Articles related to MULTIPLE SCLEROSIS (MS)

Brain Sugar Levels Act as Signal for Myelin Growth, Study Finds

Brain glucose levels regulated oligodendrocyte progenitor cell proliferation and maturation in mouse and cell models, with ketone bodies restoring myelin production when glucose use was disabled.

Neurology May 21st 2026

Tags: DIET & NUTRITION DISEASE-MODIFYING THERAPIES (DMTs) EMERGING THERAPIES MULTIPLE SCLEROSIS (MS) NEUROSCIENCE PRECLINICAL RESEARCH

MedCentral

AAN Annual Meeting 2026 Research Recap

Late-breaking sessions at AAN 2026 spanned rare disease, migraine prevention, epilepsy, FTD, MS, early Alzheimer’s, neuropathic pain, and stiff person syndrome, with mixed signals across disease-modifying and symptomatic therapies.

Neurology May 14th 2026

Tags: ALZHEIMER'S/DEMENTIA CAR T-CELL THERAPIES EPILEPSY/SEIZURES GLP-1 RECEPTOR AGONISTS MEDICAL MEETINGS AND EVENTS MIGRAINES/HEADACHES MULTIPLE SCLEROSIS (MS) PAIN MANAGEMENT RARE CONDITIONS & DISEASES RESEARCH & CLINICAL TRIALS

Neurology Advisor

EBV Antibody Titers May Distinguish MS From Other Neurologic Diseases

Persistent EBV antibody elevations distinguished MS from MOGAD and NMOSD when tracked over time in a large multicenter cohort.

Internal Medicine April 15th 2026

Tags: BIOMARKERS MULTIPLE SCLEROSIS (MS)

MedCentral

Most Industry Payments in Neurology Fall Outside the Sunshine Act

“The system lacks transparency, which was the main intent of the Sunshine Act.” — Krishna Nalleballe, MD, University of Arkansas for Medical Sciences

Neurology March 18th 2026

Tags: BUSINESS & POLICY MULTIPLE SCLEROSIS (MS) RESEARCH & CLINICAL TRIALS

Practical Neurology

Updates to the McDonald Diagnostic Criteria for Multiple Sclerosis

The 2024 McDonald criteria continue to emphasize the importance of considering differential diagnoses, including reevaluating the diagnosis periodically over the disease course, even after a diagnosis of MS has been made.

Neurology March 5th 2026

Tags: BIOMARKERS MULTIPLE SCLEROSIS (MS)

Practical Neurology

BTK Inhibitor Compared with Ocrelizumab for Primary Progressive MS

“Fenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade.” — Levi Garraway, MD, PhD, Roche Chief Medical Officer

Neurology February 19th 2026

Tags: DISEASE-MODIFYING THERAPIES (DMTs) MULTIPLE SCLEROSIS (MS) RESEARCH & CLINICAL TRIALS

1 2 … 7 8 >>

Trending Topics:

Articles related to MULTIPLE SCLEROSIS (MS)

Brain Sugar Levels Act as Signal for Myelin Growth, Study Finds

AAN Annual Meeting 2026 Research Recap

EBV Antibody Titers May Distinguish MS From Other Neurologic Diseases

Most Industry Payments in Neurology Fall Outside the Sunshine Act

Updates to the McDonald Diagnostic Criteria for Multiple Sclerosis

BTK Inhibitor Compared with Ocrelizumab for Primary Progressive MS

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form